Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
new york
3
×
new york blog main
new york top stories
3
×
san diego blog main
san diego top stories
3
×
drugs
san francisco blog main
san francisco top stories
akcea therapeutics
allergan
antibiotics
anylam pharmaceuticals
arvinas
astrazeneca
biotech
boston
boulder/denver
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
carbapenem-resistant enterobacteriaceae
cardiomyopathy
celgene
clinical data
detroit
detroit blog main
detroit top stories
entasis therapeutics
fda
genfit
gilead sciences
gritstone oncology
guardant health
indiana
What
approved
disease
drug
ago
akcea
alnylam
amyloidosis
attr
available
battle
biotechs
chose
close
company
data
debilitating
device
fatty
fda
firms
genetic
horizon
intercept
ipo
ipos
known
life
liver
make
marketed
medical
medicine
medicines
nash
new
nonalcoholic
oks
open
patients
pfizer
Language
Current search:
" new york "
×
" new york top stories "
×
" san diego top stories "
×
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
